Dialkyl phosphinates are valuable peptide mimics for metallopeptidase targets. Despite their large pharmaceutical potential, the synthesis of many phosphinates remains challenging. An additional drawback for many applications is the high polarity of the phosphinate group. Herein we describe the synthesis of stereoisomerically pure GPI (1), a phosphinate with high binding affinity for the cancer specific zinc peptidase PSMA (prostate specific membrane antigen). In addition, analogous cyclic phosphinate esters 13, 16 and 23 are reported that might be useful as less polar ligands for metallo peptidase binding. The key step to these new 1,2-oxaphosphorinan-2-ones is an intramolecular cyclization of an intermediate H-phosphinate. The cyclizations work with modest diastereoselectivities of ~2:1 in favor of the trans arrangement of substituents at 2-and 4-position of the 1,2-oxaphosphorinan-2-one scaffolds.
Introduction
Zinc containing peptidases constitute an important class of enzymes involved in tumor progression, angiogenesis, embryogenesis, ovulation and differentiation. [1] [2] An altered level of expression is often associated with malignant neoplasy. A range of metallopeptidases have therefore been used as tumor markers and are valuable targets for the development of targeted cancer therapeutics and imaging reagents. In consequence, the design and synthesis of small molecules binding to zinc peptidases with high affinity and specificity is an attractive field of Medicinal Chemistry. [3] [4] [5] The general structural requirements for small molecules in this context are a peptidomimetic backbone for recognition of the peptidase and a zinc binding moiety (Scheme 1). Suitable zinc binding groups are thiols, carboxylates, hydroxamates, phosphonates and phosphinates. In this context, thiols, hydroxamates and phosphinates belong to the strongest zinc binders and the introduction of these groups into peptidase ligands is often increasing the affinity of the ligand to the target peptidase by three to four orders of magnitude. [6] [7] [8] [9] [10] Scheme 1. Tetrahedral intermediate upon peptide hydrolysis in an active site of a zinc peptidase and a phosphinate analogue. In addition, the PSMA-specific ligand GPI (1) is shown.
Despite their large pharmaceutical potential, the synthesis of many phosphinates remains challenging. [11] [12] [13] [14] [15] [16] An additional drawback for many applications is the high polarity of the phosphinate group.
Herein we describe the synthesis of stereoisomerically pure GPI (1), a phosphinate with high binding affinity to the cancer specific zinc peptidase PSMA (prostate specific membrane antigen). In addition, analogous cyclic phosphinates are reported that might be useful as less polar precursors for metallo peptidase binding.
Results and Discussion
GPI (1), a mimic of the native dipeptide NAAG (N-acetylaspartylglutamic acid), is a high affinity binder for the tumor marker PSMA and has been used for prostate cancer targeting (Scheme 2). [17] [18] [19] It has been shown that the (S,S) diastereoisomer of GPI is the eutomer with significantly higher affinity to the target protein than the corresponding (S,R) isomer. [20] [21] However, the stereoselective synthesis of GPI proved to be difficult and only low diastereoselectivities have been realized so far. 22 For a comparative study of stereoisomeric imaging reagents based on GPI as a targeting ligand, we needed both the (S,S) and the corresponding (S,R) isomer. Following a known protocol, we started our synthesis with enantiomerically pure Cbz-(S)-vinylglycine (3), which is readily available by a two-step synthesis from Cbz-(S)-methionine (2) . 23 In parallel, dibenzyl glutarate (5) was prepared from benzyl acrylate (4) via a Baylis-Hilman type reaction with (n-Bu)3P. 24 Addition of ammonium hypophosphite gave phosphinic acid 6 as a racemate. Following a protocol of Vitharana et al., 25 stepwise crystallization with first yohimbine and second (S)-methylbenzylamine gave (S)-6 and (R)-6 in 31 and 28% yield, respectively over two steps. Both enantiomers of 6 were then treated with vinylglycine (3) and BSA to the target compounds (S,S)-7 and (S,R)-7. Both diastereomers were obtained with a de > 95 according to 1 H-NMR, proving indirectly the high enantiomeric purity of intermediate phosphinic acids (S)-6 and (R)-6 after crystallization. Scheme 2. Synthesis of (S)-vinylglycine (3) and isomerically pure (S,S)-7 and (S,R)-7. BSA = Bis(trimethylsilyl)acetamide.
The high polarity of the phosphinic acid group in peptidase inhibitors like GPI (1) is an inherent problem not only for the bioavailability of the compounds but also for workup of protected derivatives like 7. The affinity of phosphinates for silica often leads to significant loss of yield upon column chromatography. To decrease the polarity of the target compounds, we planned to introduce the dialkyl phosphinate part of the peptidase binders as a cyclic phosphinate ester (1,2-oxaphosphorinan-2-one), which upon hydrolysis would then release the phosphinic acid and an alcohol group. Our first attempt started with the conversion of allyl alcohol 8 to homoallyl alcohol 10 in a two-step procedure involving bromination and a subsequent In-mediated Barbier reaction of bromide 9 with formaldehyde (Scheme 3). The resulting homoallyl alcohol 10 was converted to the corresponding phosphinic acid ester 12. In our hands, the mixed-anhydride of phosphinic acid 11 which was prepared with pivaloyl chloride gave the best yields for this esterification. Ester 12 was then treated with BSA to give the cyclic phosphinate 13 upon intramolecular cyclization in reasonable 46% yield for the two-step sequence. Similar cyclic phosphinates have only rarely been described in the literature so far. [26] [27] [28] [29] Scheme 3. Synthesis of the cyclic phosphinate 13 via intramolecular cyclization of ester 12. BSA = Bis(trimethylsilyl)acetamide; PivCl = pivaloyl chloride; only one enantiomer of racemic compound trans-13 is shown.
The intramolecular cyclization of ester 12 to cyclic phosphinate 13 proceeds with a moderate diastereoselectivity of 2:1 in favor of trans-13. The preferred formation of trans-13 may be rationalized with the mechanistic proposal depicted in Scheme 4. Using the same approach, we have treated homoallyl alcohol 10 with phosphinic acid 14, which is readily available from (S)-vinylglycine (3). Ester 15 was again formed via the mixed anhydride of 14 with PivCl. Subsequent intramolecular cyclization gave the target cyclic phosphinate 16, which is a dipeptide mimic. Along with the methyl ester 16, we isolated a significant amount of the corresponding acid 17. Because we have used enantiomerically pure phosphonic acid 14 as a starting material, we expected the formation of all four possible stereoisomers in 16. To our surprise, we observed only two diastereoisomers in the 31 P-NMR spectra of 16 (Scheme 5, A). However, this seems to be the consequence of a coincidental signal overlap of each two stereoisomers. In the corresponding acid derivative 17, which was formed as a deprotected side product, all four isomers are observable in the 31 P-NMR spectra (Scheme 5, B). One of the reasons for synthesizing cyclic phosphinates like 13 and 16 was their decreased polarity compared to phosphinic acid analogues. In addition, we hoped that the intramolecular alkylation of the H-phosphinate intermediate might give better diastereoselectivities then acyclic variants. To introduce a chiral auxiliary in the vicinity of the newly formed stereogenic centers, we have prepared the chiral ester 20 by reaction of (-)-borneol (19) with acid 18 (Scheme 6).
Deprotection with TBAF gave alcohol 21, which was coupled to the mixed anhydride of phosphinic acid 14 to give ester 22. Intramolecular cyclization gave cyclic phosphinate 23 as a mixture of four stereoisomers. Finally, hydrolysis with aqueous HCl to 24 was performed to decrease the number of possible stereoisomers and a 2:1-mixture of two diastereoisomers was observed in the 13 C-NMR-spectra. Alternatively, the alkylation of H-phosphinate 14 with α-methylene-γ-butyrolactone (25) gave also dipeptide mimic 24, but with no diastereoselectivity at all. Scheme 6. Auxiliary synthesis of dipeptide mimic 24 via intramolecular cyclization of ester 22 and an alternative approach from α-methylene-γ-butyrolactone (25). Only one major stereoisomer for 23 and 24 is shown.
Conclusions
We have described the synthesis of isomerically pure (S,S)-and (S,R)-7 via fractional crystallization of the intermediate H-phosphinate rac-6. The target compounds 7 are protected GPI (1) derivatives and thus ligands for the prostate cancer specific peptidase PSMA. To reduce the polarity of the targeted phosphinic acids, we synthesized cyclic phosphinate esters. The key step to these new 1,2-oxaphosphorinan-2-ones is an intramolecular cyclization of an intermediate Hphosphinate. The cyclizations work with modest diastereoselectivities of ~2:1 in favor of the trans arrangement of substituents at 2-and 4-position of the 1,2-oxaphosphorinan-2-one. The resulting cyclic phosphinates are peptide mimetics of relatively low polarity compared to the corresponding acyclic phosphinic acids.
Experimental Section
General. TLC was performed on silica gel aluminium sheets (Macherey and Nagel). The reagent used for developing TLC plates was cerium stain (5g ammonium molybdate, 0.1 g cerium sulfate tetrahydrate, 10 mL sulfuric acid and 90 mL H2O) or 10% sulfuric acid in ethanol. Flash column chromatography was performed on silica gel (Macherey and Nagel, 60 -200 µm). 1 ) and NEt3 (5.13 mL, 37.0 mmol, 12.0 eq.) were added to a suspension of NH4H2PO4 (1.30 g, 15.4 mmol, 5.00 eq.) in dry CH2Cl2 (25 mL) at 0 °C. The resulting mixture was stirred for 1 h at 0 °C and a solution of 5 (1.00 g, 3.10 mmol, 1.00 eq.) in dry CH2Cl2 (1.1 mL) was added. The reaction was allowed to warm to rt and stirring was continued for 20 h before quenching with 3 M aqueous hydrochloric acid (11 mL). The residue was extracted with CH2Cl2, washed with 3 M aqueous hydrochloric acid (4 × 10 mL) and water (2 × 10 mL) and dried over sodium sulfate. Removal of the solvent in vacuo gave the target compound 6 (0.90 g, 2.31 mmol, 75%) as a colorless oil. 1 .00 mmol, 1.00 eq) was added to a solution of yohimbine•HCl (2.30 g, 6.00 mmol, 1.00 eq.) in water (10 mL) and stirred for 3 h at rt. The mixture was filtered, and the filter cake was washed with water (2 × 10 mL) and with MeOH (10 mL). Removal of the solvent in vacuo gave yohimbine (2.00 g, 5.64 mmol, 94 %) as a white solid. Yohimbine (2.00 g, 5.64 mmol, 1.00 eq.) was added to a solution of rac-6 (2.20 g, 5.64 mmol, 1.00 eq.) in acetone (11 mL) and heated to reflux for 3 h. Water (1.23 mL) was added and the mixture was cooled to -20°C, filtered and the collected solid was washed with cold acetone. The filtrate is kept for the synthesis of (S)-6. The solid was dissolved in CH2Cl2 (13 mL) and 10% sulfuric acid (2.35 mL) was added. The mixture was stirred for 30 min at rt and the phases were separated. The organic phase was washed with 10% sulfuric acid (2 × 10 mL) and water (2 × 10 mL). Removal of the solvent in vacuo gave the target molecule (R)-6 (0.62 g, 1.59 mmol, 28%) as a colorless oil. , 1 .00 eq.) was added to the filtrate of the procedure above and the resulting mixture was heated to reflux for 3 h. The reaction was cooled to -20°C, filtered and the collected solid was washed with cold acetone. The solid was dissolved in CH2Cl2 (20 mL) and 2 M aqueous hydrochloric acid (10 mL) was added. The solution was stirred for 30 min at rt and the phases were separated. The organic phase was washed with 2 M aqueous hydrochloric acid (2 × 20 mL) and water (2 × 20 mL). Removal of the solvent in vacuo gave the target molecule (S)-6 (0.74 g, 1.90 mmol, 31%) as a colorless oil. 1 
((R)-5-(Benzyloxy)-2-((benzyloxy)carbonyl)-5-oxopentyl)((S)-3-(((benzyloxy)carbonyl)amino)-4-methoxy-4-oxobutyl)phosphinic acid ((S,R)-7):
To a solution of (R)-6 (0.31 g, 0.79 mmol, 1.00 eq.) in CH2Cl2 (5 mL) was added N,O-Bis(trimethylsilyl)acetamide (0.59 mL, 1.59 mmol, 2.00 eq.) and the mixture was heated to reflux for 4 h. (S)-Vinylglycine (3) (0.20 g, 0.79 mmol, 1.00 eq.) was added and the reaction was heated to reflux for 72 h. The reaction was quenched with 2 M aqueous hydrochloric acid (3 mL) and the mixture was washed with 2 M aqueous hydrochloric acid (2 × 5 mL). The solvent was removed in vacuo and the residue was purified by flash chromatography (EtOAc  EtOH) to give the target compound (S,R)-7 (0.29 g, 0.45 mmol, 56%) as a colorless solid. 
((S)-5-(Benzyloxy)-2-((benzyloxy)carbonyl)-5-oxopentyl)((S)-3-(((benzyloxy)carbonyl)amino)-4-methoxy-4-oxobutyl)phosphinic acid ((S,S)-7):
To a solution of (S)-6 (0.44 g, 1.13 mmol, 1.00 eq.) in CH2Cl2 (10 mL) was added N,O-Bis(trimethylsilyl)acetamide (1.11 mL, 4.52 mmol, 4.00 eq.) and the mixture was heated to reflux for 4 h. (S)-Vinylglycine (3) (0.28 g, 1.13 mmol, 1.00 eq.) was added and the reaction was heated to reflux for 120 h. The reaction was quenched with 2 M aqueous hydrochloric acid (3 mL) and the organic phase was washed with 2 M aqueous hydrochloric acid (2 × 10 mL). The solvent was removed in vacuo and the residue was purified by flash chromatography (EtOAc/PE, 1:1  EtOH) to give the target compound (S,S)-7 (0.38 g, 0.59 mmol, 53%) as a colorless solid. 52 (m, 1 H, 1-H), 1.19 -1.25 (m, 1 H, 1'-H (3-(tert-butoxy)-3-oxopropyl)-1,2 -oxaphosphinane-4-carboxylate 2-oxide 13. H-Phosphinate 11 (47 mg, 0.24 mmol; 1 eq.) was dissolved in 3 mL dry MeCN and 1 mL dry pyridine. Pivaloyl chloride (60 μL, 0.48 mmol; 2 eq.) and ester 10 (41 mg, 0.24 mmol; 1 eq.) were added and the solution was stirred at rt under nitrogen atmosphere for 1h. The solvent was removed in vacuo to give the crude phosphinate 12, which was dissolved in CH 2 Cl 2 (4 mL). N,OBis(trimethylsilyl)acetamid (BSA) (0.24 mL, 0.95 mmol; 6 eq.) was added and the solution was stirred for 96 h at rt under nitrogen atmosphere. The solution was treated with aqueous 1N HCl (2 mL), phases were separated and the organic phase was evaporated to dryness in vacuo. The residue was purified by column chromatography on silica (EtOAc:MeOH, 50:3) to give the title compound 13 (38 mg, 46%) as a 2 and ester 10 (28 mg, 0.16 mmol; 1 eq.) were added and the solution was stirred at rt under nitrogen atmosphere for 48h. The solvent was removed in vacuo to give the crude phosphinate 15, which was dissolved in CH2Cl2 (4 mL). N,O-Bis(trimethylsilyl)acetamid (BSA) (0.24 mL, 0.95 mmol; 6 eq.) was added and the solution was stirred for 96 h at rt under nitrogen atmosphere. The solution was treated with aqueous 1N HCl (2 mL), phases were separated and the organic phase was evaporated to dryness in vacuo. The residue was purified by column chromatography on silica (EtOAc:MeOH, 25:1) to give the title compound 16 (22 mg , 1 H, 3b-H), 0.92 (s, 3 H, 8-H), 0.88 (s, 3 H, 8-H), 0.81 (s, 3 H, 1''-H) . 13 The TBDPS-protected ester 20 (500 mg, 1.02 mmol; 1 eq.) was dissolved in abs THF (10 mL) and cooled to 0 °C. TBAF • 3 H2O (644 mg, 2.04 mmol; 2 eq.) was coevaporated three times with CH2Cl2, dissolved in THF (5 mL) and added to the reaction mixture drop wise. The solution was stirred for 5 h at 0 °C und nitrogen atmosphere. Aqueous saturated NH4Cl solution (10 mL) was added and the mixture was extracted three times with each 20 mL EtOAc. The combined organics were dried over Na2SO4, filtered and the solvent was removed in vacuo. The residue was purified by column chromatography on silica (CH2Cl2:MeOH-20:1) to give the title compound 21 as a colorless oil (207 mg, 80%). Rf: 0.08 (SiO2, CH2Cl2). 
